Inhibitory Effects of Kaempferitrin on Human Liver Cytochrome P450 Enzymes

Overview

Journal Pharm Biol

Specialties Pharmacology
Pharmacy

Date 2019 Aug 29

PMID 31456483

Citations 5

Authors

Ning Zhang

Jing Liu

Zhixia Chen

Wenwen Dou

Affiliations

Soon will be listed here.

Abstract

Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. This study investigates the effects of KF on eight major CYP isoforms in human liver microsomes (HLMs). , HLMs were used to investigate the inhibitory effects of KF (100 μM) on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8), and corresponding probe substrates were used. Enzyme kinetic studies (0-50 μM of KF) were conducted to determine the inhibition mode of KF on CYP enzymes. The results showed that KF inhibited the activity of CYP1A2, 3A4, and 2C9, with IC values of 20.56, 13.87, and 14.62 μM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that KF was not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP1A2 and 2C9, with values of 7.11, 10.24, and 7.58 μM, respectively. In addition, KF is a time-dependent inhibitor for CYP3A4 with / value of 10.85/0.036 min/μM. The studies of KF with CYP isoforms indicate that KF has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4, and 2C9. It is recommended that KF should not be used with other drugs metabolized by CYP1A2, 3A4, and 2C9. Further clinical studies are needed to evaluate the significance of this interaction.

Citing Articles

Flavonoids as CYP3A4 Inhibitors In Vitro.

Kondza M, Brizic I, Jokic S Biomedicines. 2024; 12(3).

PMID: 38540257 PMC: 10968035. DOI: 10.3390/biomedicines12030644.

Inhibitory effects of Triphala on CYP isoforms and its pharmacokinetic interactions with phenacetin and midazolam in rats.

Nontakham J, Siripong P, Sato H, Chewchinda S, Arunrungvichian K, Yahuafai J Heliyon. 2022; 8(6):e09764.

PMID: 35785236 PMC: 9243172. DOI: 10.1016/j.heliyon.2022.e09764.

Alpinetin suppresses CYP3A4, 2C9, and 2E1 activity .

Song H, Wei C, Yang W, Niu Z, Gong M, Hu H Pharm Biol. 2022; 60(1):1032-1037.

PMID: 35634649 PMC: 9154758. DOI: 10.1080/13880209.2022.2071450.

The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms.

Danek P, Bromek E, Daniel W Pharmaceuticals (Basel). 2021; 14(7).

PMID: 34209648 PMC: 8308745. DOI: 10.3390/ph14070629.

inhibitory effects of ganoderic acid A on human liver cytochrome P450 enzymes.

Xu S, Zhang F, Chen D, Su K, Zhang L, Jiang R Pharm Biol. 2020; 58(1):308-313.

PMID: 32285742 PMC: 7178866. DOI: 10.1080/13880209.2020.1747500.

References

Zhang H, Ya G, Rui H . Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein. Eur J Drug Metab Pharmacokinet. 2016; 42(1):89-98. DOI: 10.1007/s13318-016-0323-8. View

Singh A, Pant M, Ruwali M, Shah P, Prasad R, Mathur N . Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark. 2011; 8(6):351-9. DOI: 10.3233/CBM-2011-0224. View

Alonso-Castro A, Ortiz-Sanchez E, Garcia-Regalado A, Ruiz G, Nunez-Martinez J, Gonzalez-Sanchez I . Kaempferitrin induces apoptosis via intrinsic pathway in HeLa cells and exerts antitumor effects. J Ethnopharmacol. 2012; 145(2):476-89. DOI: 10.1016/j.jep.2012.11.016. View

Zhang Q, Hu J, Wang B, Li Y . Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012; 14(4):382-95. DOI: 10.1080/10286020.2012.656605. View

Hu X, Huang W, Yang Y . Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii. Eur J Drug Metab Pharmacokinet. 2014; 40(4):373-7. DOI: 10.1007/s13318-014-0219-4. View

da Silva D, Casanova L, Marcondes M, Espindola-Netto J, Paixao L, De Melo G . Antidiabetic activity of Sedum dendroideum: metabolic enzymes as putative targets for the bioactive flavonoid kaempferitrin. IUBMB Life. 2014; 66(5):361-70. DOI: 10.1002/iub.1270. View

Zhang J, Liu Y, Cheng J, Li W, Ma H, Liu H . Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci. 2008; 10(4):496-503. DOI: 10.18433/j30593. View

Lang J, Li W, Zhao J, Wang K, Chen D . Inhibitory effects of curculigoside on human liver cytochrome P450 enzymes. Xenobiotica. 2016; 47(10):849-855. DOI: 10.1080/00498254.2016.1257171. View

Li A . Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today. 2001; 6(7):357-366. DOI: 10.1016/s1359-6446(01)01712-3. View

10.

Lim Y, Chen W, Cheng C, Ma W, Lin Y, Chen C . Inhibition of cytochrome P450 2C9 expression and activity in vitro by allyl isothiocyanate. Planta Med. 2014; 80(13):1097-106. DOI: 10.1055/s-0034-1383000. View

11.

Wrighton S, Stevens J . The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22(1):1-21. DOI: 10.3109/10408449209145319. View

12.

Fang Z, Zhang Y, Ge G, Huo H, Liang S, Yang L . Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol. 2010; 69(2):193-9. PMC: 2824481. DOI: 10.1111/j.1365-2125.2009.03572.x. View

13.

Zhou S . Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab. 2008; 9(4):310-22. DOI: 10.2174/138920008784220664. View

14.

Hamzah A, Lajis N, Sargent M . Kaempferitrin from the leaves of Hedyotis verticillata and its biological activity. Planta Med. 1994; 60(4):388-9. DOI: 10.1055/s-2006-959513. View

15.

Song Y, Weng Z, Dou T, Finel M, Wang Y, Ding L . Inhibition of human carboxylesterases by magnolol: Kinetic analyses and mechanism. Chem Biol Interact. 2019; 308:339-349. DOI: 10.1016/j.cbi.2019.06.003. View

16.

Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y . Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol. 1998; 38:461-99. DOI: 10.1146/annurev.pharmtox.38.1.461. View

17.

Zhang J, Li C, Zhang J, Zhang F . inhibitory effects of sophocarpine on human liver cytochrome P450 enzymes. Xenobiotica. 2018; 49(10):1127-1132. DOI: 10.1080/00498254.2018.1468047. View

18.

Qi X, Liang S, Ge G, Liu Y, Dong P, Zhang J . Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol. 2013; 56:392-7. DOI: 10.1016/j.fct.2013.02.054. View

19.

Kirby B, Unadkat J . Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab Dispos. 2010; 38(11):1926-33. PMC: 2967394. DOI: 10.1124/dmd.110.034736. View

20.

Jeong H, Kong T, Kwon S, Hong S, Yeon S, Choi J . Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 2013; 18(9):10681-93. PMC: 6269737. DOI: 10.3390/molecules180910681. View